Copaxone Related Published Studies
Well-designed clinical trials related to Copaxone (Glatiramer)
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. [2013]
Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]
Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. [2011.01]
Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. [2010.11]
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. [2010.03]
Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. [2010.02]
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis:
results from the 15-year analysis of the US prospective open-label study of
glatiramer acetate. [2010]
New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. [2009.12]
Glatiramer acetate treatment in PPMS: why males appear to respond favorably. [2009.11.15]
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. [2009.10.31]
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. [2009.10]
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. [2009.10]
250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. [2009.10]
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. [2009.06.09]
Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. [2009]
[Long-term effects of glatiramer acetate in multiple sclerosis] [2008.11]
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. [2008.10]
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. [2008.10]
Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. [2008.08]
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. [2008.06]
Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. [2008.05]
Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. [2008.01]
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. [2007.08]
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. [2007.05]
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. [2007.03.20]
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. [2007.01]
During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. [2006.08]
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. [2006.06]
Randomized controlled phase II trial of glatiramer acetate in ALS. [2006.04.11]
Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. [2006.03]
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. [2005.01]
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. [2003.12]
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. [2003.08]
Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. [2002.10.22]
Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. [2001.09]
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. [2001.03]
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. [2001.03]
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. [2001.02]
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. [2000.08]
Neuropsychologic status in multiple sclerosis after treatment with glatiramer. [1999.03]
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. [1998.03]
Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone). [1996.07]
Well-designed clinical trials possibly related to Copaxone (Glatiramer)
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in
patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM
study. [2014]
Recruitment of participants to a multiple sclerosis trial: the CombiRx
experience. [2014]
Pharmacological treatment for memory disorder in multiple sclerosis. [2013]
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. [2011.10.25]
A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. [2010.09]
Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. [2010.08.25]
Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. [2010.06]
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? [2010.04]
Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. [2010.03]
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of
relapsing multiple sclerosis. [2010]
Two-year study of cervical cord volume and myelin water in primary progressive
multiple sclerosis. [2010]
Results of a phase I study in patients suffering from secondary-progressive
multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301
and a possible induction of an anti-inflammatory cytokine response. [2010]
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? [2010]
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.11.10]
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. [2009.11.03]
Serum levels of CXCL13 are elevated in active multiple sclerosis. [2009.11]
Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? [2009.08]
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. [2009.03.03]
Effect of textured foot orthotics on static and dynamic postural stability in middle-aged females. [2008.01]
Cost-Effectiveness Analyses of Natalizumab (Tysabri((R))) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. [2008]
Outcome measures for early phase clinical trials. [2007.10]
The Timed Up and Go test: predicting falls in ALS. [2007.10]
Clinical and microbiologic changes associated with the combined use of a powered toothbrush and a triclosan/copolymer dentifrice: a 3-year prospective study. [2007.09]
Comparative Efficacy of Stabilized Stannous Fluoride/Sodium Hexametaphosphate Dentifrice and Sodium Fluoride/Triclosan/Copolymer Dentifrice for the Prevention of Periodontitis in Xerostomic Patients: A 2-Year Randomized Clinical Trial. [2007.08]
Clinical and radiographic evaluation of the effects of guided tissue regeneration using resorbable membranes after extraction of impacted mandibular third molars. [2007.02]
Oral hygiene regimens, plaque control, and gingival health: a two-month clinical trial with antimicrobial agents. [2007]
Mycophenolate mofetil in multiple sclerosis. [2004.03]
Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]
Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. [2003.01]
Randomized controlled trials to assess therapies for multiple sclerosis. [2002.04.23]
MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. [2002.02.12]
Copolymer-1. [1997.10]
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. [1996.04]
Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. [1996.04]
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. [1995.07]
Other research related to Copaxone (Glatiramer)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple
sclerosis. [2014]
Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. [2011.09]
Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. [2011.09]
Recent insights into the mechanism of action of glatiramer acetate. [2011.06]
Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica. [2011.06]
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. [2011.05.01]
Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis. [2011.05]
Glatiramer acetate attenuates neuropathic allodynia through modulation of adaptive immune cells. [2011.05]
Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). [2011.03.30]
Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. [2011.02.15]
Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone. [2011.02]
Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. [2011]
Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. [2010.08.25]
Glatiramer acetate for multiple sclerosis. [2010.05.12]
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. [2010.05]
Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. [2010.04]
Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate. [2010.04]
Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. [2010.03.30]
Glatiramer acetate immune system augmentation for peripheral nerve regeneration in rat crushed sciatic nerve model. [2010.02]
The mechanism of action of glatiramer acetate treatment in multiple sclerosis. [2010.01.05]
Allergy workup in immediate-type local reactions to glatiramer acetate. [2010]
Tolerability and safety of novel half milliliter formulation of glatiramer
acetate for subcutaneous injection: an open-label, multicenter, randomized
comparative study. [2010]
Glatiramer acetate for multiple sclerosis. [2010]
Effect of oral antihistamine on local injection site reactions with
self-administered glatiramer acetate. [2010]
|